Royalty Report: Pain, Drugs, Pharmaceuticals – Collection: 5599

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Pain
  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Nerve
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5599

License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and  granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI).  It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 28851

License Grant
The restated agreement amends among other items, the sales obligations in respect of bicifadine, ocinaplon and the Company's 216,303.
License Property
Bicifadine is for the treatment of pain.  Ocinaplon is for the treatment of anxiety. The Company's 216,303 is for the treatment of depression.

IPSCIO Record ID: 230815

License Grant
Licensor shall grant the Licensee of Ireland a non-exclusive license, including the right to grant sublicense, of the Licensor Intellectual Property solely in the Field and in particular to make, have made, import, use, offer for sale and sell the Products in the Territory.

Licensor shall grant a non-exclusive sublicense of Licensors interests and entitlements solely in the Field under another Agreement in the anothers Know-How and the anothers patent Rights relating to the Compounds in the Territory, with the right to grants sublicenses.

License Property
Compounds shall mean the Licensor compounds named 220,075 and 273,547, the rights to which were licensed by Licensor pursuant to the ACY Agreement.

Product 220,075 shall mean , the twice daily oral formulation(s} using the Intellectual Property and incorporating the compound 220,075 (bicifadine- analgesic) utilizing the Technologies.

Product 273,547 shall mean the once daily oral formulation using the Intellectual Property and incorporating the compound 273,547 (nonbenzodiazapinen anxiolytic) utilizing the Technologies.

Field of Use
Field shall mean the research, development and commercialization of oral Controlled Release formulations of the Products.

IP relates to a controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

IPSCIO Record ID: 3563

License Grant
Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses.

They entered into an  license agreement for the development and commercialization of Fado (Fadolmidine) for use as a human therapeutic, in any dosage form.

License Property
Fado is in a class of drugs called alpha-2 adrenergic agonists, which produce their effects by selectively activating the alpha-2 adrenergic receptors in the body and produce a broad range of effects depending on the specific drug and the alpha-receptors it activates, including anti-hypertensive, analgesic and sedative effects. Fado shows promise in neuropathic pain. It does not cross the blood brain barrier and this accounts for the targeting of Fado use for either IT administration for pain or anesthesia, or potentially for topical use to treat pain associated with regional nerve pain from underlying nerve damage, also called “neuropathies.”

U.S patent numbers (6313311; 7759496; 6479530; 6495584)

Field of Use
Fado is a product candidate to be used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Licensee intends to pursue as a topical product for local application to treat serious pain associated with neuropathies, especially of the lower extremities, which can occur in diabetic patients.

IPSCIO Record ID: 5590

License Grant
We licensed from the Licensee, on an exclusive, worldwide basis, indiplon, bicifadine, ocinaplon and DOV 216,303 for any indication, including insomnia, pain, anxiety and depression.  We have the right to develop and commercialize these compounds, including the right to grant sublicenses to third parties, subject to the Licensee’s right of first refusal.
License Property
BICIFADINE
UNITED STATES

U.S. 4,196,120 – expires 4/1/97

U.S. 4,231,935 – expires 11/4/97

U.S. 4,435,419 – expires 7/1/01

USSN 08/122,856 – pending

USSN 08/414,180 – pending

CL 216,303

UNITED STATES

U.S. 4,196,120 – expires 4/1/97

U.S. 4,231,935 – expires 11/4/97

U.S. 4,435,419 – expires 7/1/01

USSN 08/122,856 – pending

USSN 08/414,180 – pending

CL 273,547

UNITED STATES

U.S. 4,521,422 – expires 6/23/03
4,196,120 Substituted 3-azabicyclo[3.1.0 hexanes, acid addition salts, method of use and method of preparation are described. The compounds have anxiolytic and analgesic activity.

IPSCIO Record ID: 33525

License Grant
The Israel Company entered into this Development, Manufacturing and Commercialization Agreement with a major Chinese pharmaceutical company for the Pregabalin ER product in the Chinese territory for commercialization of the products in the territory.
License Property
The Pregabalin ER product is an extended release oral form for the treatment of neuropathic pain and epilepsy.
Field of Use
This agreement pertains to the drug industry relating to neuropathic pain and epilepsy.

IPSCIO Record ID: 28144

License Grant
The Licensee entered into a binding memorandum of understanding the Israeli Licensor, the technology transfer company of the University, regarding certain patents in connection with nanoparticles for topical delivery of the Licensee's neuropathic pain drug candidate ready for a Phase III clinical trial. The parties will be entered into a definitive license agreement within six months of the date of the MOU for the commercial development and marketing of the Technology worldwide.
License Property
The Licensor's patents in connection with nanoparticles for topical delivery for the Licensee's neuropathic pain drug candidate.
Field of Use
The pain compound AmiKetâ„¢, a topical cream consisting of a patented combination of amitriptyline and ketamine that is in late stage development for the treatment of peripheral neuropathies and has received Orphan Drug Designation for Post Herpetic Neuralgia.

IPSCIO Record ID: 2893

License Grant
We have entered into an exclusive License Agreement relating to U.S. Patent No. 6,610,324 and its foreign equivalents, entitled Flupirtine in the treatment of fibromyalgia and related conditions.  Flupirtine, an aminopyridine  is a centrally acting nonopioid analgesic.
License Property
Flupirtine is an aminopyridine that functions as a centrally acting non-opioid analgesic that was originally used as an analgesic for acute and chronic pain.

Fibromyalgia is a common condition characterized by long-term, body-wide pain and tender points in joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, morning stiffness, sleep problems, headaches, numbness in hands and feet, depression, and anxiety.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 319352

License Grant
Licensor (of the United Kindgom) granted Licensee the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing Licensor’s spray formulation technology (Licensor Product), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses).
License Property
Topical Spray Technology product mean DSF100 or EpoladermTM and OSF200, a topical nonsteroidal anti-inflammatory drug. This Technology is a therapeutic treatment for topicals and transdermal deliveries due to its adhesion and accessibility properties, especially around joints and curved body surfaces.

OSF200 – for chronic osteoarthritis of the knee
DSF100 or EpoladermTM – for acute musculoskeletal pain

The product candidate is covered by US Patent No. 8,349,297. The patents contain broad composition claims to a platform of pharmaceutical formulations which form a film on spray administration where the active agent is present at least 80% saturation and there is no undissolved active agent in the formulation. The claims also include a method of treatment and an aerosol dispenser containing the formulation.

8,349,297 – Topical formulations

Field of Use
The field of use is for the treatment of pain to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses) and not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain such as acute musculoskeletal pain and chronic osteoarthritis of the knee.

IPSCIO Record ID: 26587

License Grant
We have licensed exclusive, worldwide, development and commercialization rights under an Agreement.

Remoxy is formulated with our Oradur technology and incorporates several abuse-deterrent properties with the convenience of twice-a-day dosing. Oxycodone is also the active drug ingredient in OxyContin®, a brand name narcotic painkiller.  Remoxy is intended for patients with chronic pain. Remoxy is currently in Phase III trials.

Field of Use
The rights granted apply to the pain management industry.

IPSCIO Record ID: 28803

License Grant
Licensor granted the Company an exclusive license in the United States and its possessions and territories, with defined sub-license rights to third parties other than certain technological competitors of Licensor, to certain Licensor intellectual property rights related to the Company’s Zohydro ER product candidate.
License Property
Zohydro ER (hydrocodone bitartrate) extended release capsuls for chronic pain.

Zohydro ER is an opioid agonist, extended-release oral formulation of hydrocodone without acetaminophen, for the management of sever pain enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

IPSCIO Record ID: 329681

License Grant
University hereby grants the License to the Licensee and its Affiliates  (i) an exclusive, worldwide right and license under the Patent Rights and (ii) a non-exclusive, worldwide right and license to the University Know-How to (a) make, have made, use, research, develop, have developed, lease, market, offer to sell, sell, have sold, distribute, improve, import and export Licensed Products and Licensed Processes in the Field; and (b) otherwise practice the Invention in the Field.
License Property
US Patent #6,248,744 – Method for the treatment of pain, including chronic and female specific pain.

Invention means University#98-14 Sex Related Deference in Pain Relief from Spinal Compound (RJR 2403)

VCU Patents  S Patent #5,914,337 – Compounds and pharmaceutical compositions thereof for eliciting analgesic effects

Field of Use
Field of use is for the treatment of pain relief.

TC-2696 for the treatment of chronic or female-specific pain.  TC-2696 is a novel small molecule that we are developing as an oral treatment for acute post-operative pain.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.